A detailed history of Laurel Wealth Advisors, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Laurel Wealth Advisors, Inc. holds 1,100 shares of ALNY stock, worth $267,575. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,100
Previous 1,100 -0.0%
Holding current value
$267,575
Previous $220,000 18.64%
% of portfolio
0.03%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $152,394 - $255,200
1,100 New
1,100 $220,000
Q4 2021

Feb 14, 2022

SELL
$159.56 - $209.29 $181,419 - $237,962
-1,137 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $193,005 - $236,189
1,137 New
1,137 $215,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Laurel Wealth Advisors, Inc. Portfolio

Follow Laurel Wealth Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Laurel Wealth Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Laurel Wealth Advisors, Inc. with notifications on news.